Natural History Studies: Launch With Care And Consider Alternative Evidence For Drug Approval, FDA’s Marks Says

 
• By Sue Sutter
  
Rocket launch
Launching natural history studies requires careful consideration, CBER Director Peter Marks said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards